Skip to main content

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients

Cancer Immunology, Immunotherapy volume 69, pages 365–372 (2020)Cite this article

Abstract

Immune checkpoint inhibitors (ICIs) represent a major breakthrough for cancer treatment. However, evidence regarding the use of ICIs in pancreatic cancer (PC) remained scarce. To assess the efficacy and safety of ICIs plus chemotherapy, patients with advanced PC were retrospectively recruited and were treated with either chemotherapy alone or chemotherapy plus ICIs. Patients previously treated with any agents targeting T-cell co-stimulation or checkpoint pathways were excluded. The primary outcome was overall survival (OS). The secondary outcomes were progression-free survival (PFS), overall response rate (ORR) and safety. In total, 58 patients were included (combination, n = 22; chemotherapy, n = 36). The combination group showed a significantly longer OS than the chemotherapy group [median, 18.1 vs 6.1 months, hazard ratio (HR) 0.46 (0.23–0.90), P = 0.021]. The median PFSs were 3.2 months in the combination group and 2.0 months in the chemotherapy group [HR 0.57 (0.32–0.99), P = 0.041]. The combination group and the chemotherapy group had similar ORRs (18.2% vs 19.4%, P = 0.906). All patients who achieved a partial response received a doublet chemotherapy regimen regardless of co-treatment with ICIs. Grade 3 or higher adverse events occurred in 31.8% of the patients in the combination group and in 16.9% of those receiving chemotherapy. Although the incidence of serious treatment-related adverse events was higher in the combination group than in the chemotherapy group, the difference was not significant (P = 0.183). Our findings suggest that the combination of ICIs with chemotherapy is both effective and tolerable for advanced PC. ICIs combined with a doublet chemotherapy regimen might be a preferable choice.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

Abbreviations

ASCO:

American Society of Clinical Oncology

ASCO-GI:

American Society of Clinical Oncology-gastrointestinal cancer

CR:

Complete response

DCR:

Disease control rate

ECOG:

Eastern Cooperative Oncology Group

FOLFIRINOX:

Fluorouracil/leucovorin plus irinotecan plus oxaliplatin

GEST:

Gemcitabine and S-1 Trial

HR:

Hazard ratio

ICI:

Immune checkpoint inhibitor

dMMR:

Mismatch repair deficient

mOS:

Median overall survival

mPFS:

Median progression-free survival

MSI-H:

Microsatellite instability-high

ORR:

Overall response rate

PC:

Pancreatic cancer

PR:

Partial response

PS:

Performance status

SD:

Stable disease

TRAE:

Treatment-related adverse event

References

  1. Sun DY, Ma JX, Wang JL, Han C, Qian YY, Chen GY et al (2019) Anti-PD-1 therapy combined with chemotherapy in patients with advanced pancreas cancer in a real-world clinical setting. J Clin Oncol 37(15_suppl):e14103 (Abstract)

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30

    Article  Google Scholar 

  3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267

    Article  Google Scholar 

  4. van Roessel S, Kasumova GG, Verheij J, Najarian RM, Maggino L, de Pastena M, International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) et al (2018) TNM staging system in patients with resected pancreatic cancer. JAMA Surg 153:183617

    Article  Google Scholar 

  5. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    CAS  Article  Google Scholar 

  6. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

    Google Scholar 

  7. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

    CAS  Article  Google Scholar 

  8. Hammers H, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF et al (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. Ann Oncol 25(suppl):iv361–iv362 (abstr)

    Article  Google Scholar 

  9. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920

    CAS  Article  Google Scholar 

  10. Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M et al (2017) Avelumab for metastatic or locally advanced previously treated solid tumors (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587–598

    CAS  Article  Google Scholar 

  11. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520

    CAS  Article  Google Scholar 

  12. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S et al (2017) Hypermutation in pancreatic cancer. Gastroenterology 152:68–74

    CAS  Article  Google Scholar 

  13. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567

    CAS  Article  Google Scholar 

  14. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M et al (2015) Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293

    CAS  Article  Google Scholar 

  15. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US et al (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828–833

    CAS  Article  Google Scholar 

  16. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–442

    CAS  Article  Google Scholar 

  17. Vonderheide RH, Bayne LJ (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 25:200–205

    CAS  Article  Google Scholar 

  18. Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL et al (2015) Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 3:399–411

    CAS  Article  Google Scholar 

  19. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39:74–88

    CAS  Article  Google Scholar 

  20. Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13:143–158

    CAS  Article  Google Scholar 

  21. Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E et al (2018) Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investig New Drugs 36:96–102

    CAS  Article  Google Scholar 

  22. Borazanci EH, Jameson GS, Board MJ, Ramanathan RK, Korn RL, Caldwell L et al (2018) A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 36(4suppl):abstract358

    Article  Google Scholar 

  23. Renouf DJ, Dhani NC, Kavan P, Jonker DJ, Wei ACC, Hsu T et al (2018) The Canadian Cancer Trials Group PA.7 trial: results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol 36(4suppl):abstract349

    Article  Google Scholar 

  24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    CAS  Article  Google Scholar 

  25. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC et al (2012) Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J AM Acad Dermatol 67:1025–1039

    Article  Google Scholar 

  26. Des Jarlais DC, Lyles C, Crepaz N, TREND Group (2005) Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 94:361–366

    Article  Google Scholar 

  27. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G et al (2010) Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 23:1183–1192

    Article  Google Scholar 

  28. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557

    CAS  Article  Google Scholar 

  29. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648

    CAS  Article  Google Scholar 

  30. Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H et al (2008) A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 113:2448–2456

    CAS  Article  Google Scholar 

  31. Zhang SH, Liu GF, Li XF, Liu L, Yu SN (2018) Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: a network meta-analysis. J Cell Physiol 233:3352–3374

    CAS  Article  Google Scholar 

  32. Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25

    CAS  Article  Google Scholar 

  33. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215–233

    CAS  Article  Google Scholar 

  34. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4013–4905

    Article  Google Scholar 

  35. Plate JM, Plate AE, Shott S, Bograd S, Harris JE (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915–925

    CAS  Article  Google Scholar 

  36. Soliman HH (2016) Nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther 10:101–112

    Article  Google Scholar 

  37. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank the patients and their families.

Funding

This work was funded by the National Natural Science Foundation of China [81402552 to Yi Hu, 81672996 to Yi Hu].

Author information

Author notes

  1. Junxun Ma and Danyang Sun are co-first authors.

Affiliations

  1. Department of Medical Oncology, Chinese People’s Liberation Army General Hospital, 28 Fuxing Road, Haidian, Beijing, 100853, People’s Republic of China

    Junxun Ma, Jinliang Wang, Chun Han, Yuanyu Qian, Guangying Chen, Xiaoyan Li, Juan Zhang, Pengfei Cui, Wushuang Du, Zhaozhen Wu, Shixue Chen, Xuan Zheng, Zhichao Yue & Yi Hu

  2. Intensive Care Unit, West Ward, China-Japan Friendship Hospital, Beijing, People’s Republic of China

    Danyang Sun

  3. The Medical Department, 3D Medicines Inc., 158 Xinjunhuan Road, Minhang, Shanghai, 201114, People’s Republic of China

    Jia Song, Chan Gao & Shangli Cai

Authors
  1. Junxun Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danyang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinliang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuanyu Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guangying Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoyan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pengfei Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wushuang Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zhaozhen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shixue Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xuan Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Zhichao Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jia Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Chan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Shangli Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yi Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: JXM, DYS, SLC and YH. Protocol writing: JXM, DYS, JS, SLC and YH. Data collection: CH, JLW, YYQ, GYC, XYL, PFC, JZ, WSD, SXC, ZZW, XZ and ZCY. Data analysis: JS, JXM and CG. Manuscript writing: JS, JXM, DYS and JLW. Manuscript revisions: CG, YH and SLC. All authors contributed to writing and reviewing the manuscript and approved the final version of the manuscript.

Corresponding authors

Correspondence to Shangli Cai or Yi Hu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval and ethical standards

The study was approved by the institutional review board of the People’s Liberation Army General Hospital, Beijing, China (approval number: S2018-144-02). This clinical study was conducted in accordance with the Helsinki declaration and its later amendments.

Informed consent

Because of the retrospective nature of the study, informed consent was waived by the People’s Liberation Army General Hospital, Beijing. This paper does not contain any individual person’s data in any form.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Parts of the data have been published as an abstract at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting which was held during May 31–June 4, in Chicago, IL, USA [1].

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 288 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ma, J., Sun, D., Wang, J. et al. Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunol Immunother 69, 365–372 (2020). https://doi.org/10.1007/s00262-019-02452-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-019-02452-3

Keywords

  • Pancreatic cancer
  • Immune checkpoint inhibitors
  • Combination therapy
  • Efficacy
  • Safety